TSX:CRONPharmaceuticals
The Bull Case For Cronos Group (TSX:CRON) Could Change Following Partial U.S. Cannabis Rescheduling Shift
The U.S. Department of Justice has moved to reclassify certain marijuana products from Schedule I to Schedule III, easing tax and funding constraints for state-licensed and FDA-approved cannabis businesses, including Cronos Group, although broader rescheduling remains under expedited review.
This partial shift in federal treatment of marijuana highlights how uneven regulatory changes can advantage some cannabis operators over others, making policy nuance increasingly important for Cronos...